Castor, a health-tech company that says it enables medical researchers to capture machine readable data to optimise medical decision making, is introducing its global COVID-19 monitoring and research platform to facilitate the rapid deployment of trials to test Coronavirus vaccines and COVID-19 treatments, it was reported on Thursday.
The company is now supporting more than 50 studies.
The firm's platform has an online enrolment portal for patients, an eConsent module, and a Symptom Tracker app, all merged with the company's Electronic Data Capture (EDC) system. This platform is freely available for everyone fighting COVID-19, including biotechnology and pharmaceutical companies. The platform was designed to be rapidly configured and deployed. After an online enrolment and eConsent, patients and are randomised in the EDC. Depending on country protocols, vaccines can then be shipped to enrolled patients and administered in their homes. The real-time dashboards also allow study personnel to monitor the population and proactively reach out to patients who are showing symptoms of COVID-19. These patients could then be enrolled in further interventional studies or triaged in a hospital.
Alongside this platform, Castor is supporting research into the disease by providing free access to its research data platform for all COVID-19 studies.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study